精心规划的加速部分乳腺照射每日两次或隔日方案美容效果优良率高
本研究回顾245例接受外照射加速部分乳腺照射(EB-APBI)的患者,采用严格轮廓勾画与剂量学规划,55%每日两次、45%隔日照射。中位随访19个月,优良美容率97.1%,急毒性低,提示该规划方式下两种分次方案均可获得良好美容效果。
要点
- 严格规划下EB-APBI每日两次或隔日方案优良美容率达97.1%。
- 急毒性低,55%无皮炎、57%无乏力、97%无瘙痒。
核心结论
- 采用多野三维适形、俯卧位及严格规划指南的EB-APBI,每日两次或隔日分次均可实现极低毒性和优良美容效果。
研究设计与样本
- 中位年龄66岁(IQR 59-71岁),82%为浸润性乳腺癌,100%浸润性肿瘤为激素受体阳性/HER2阴性,96%浸润性疾病接受淋巴结手术。
- 55%患者每日两次分次,45%隔日分次;88%使用三维适形放疗,中位6野,96%俯卧位治疗。
主要发现
- 优良美容率97.1%(n=238),一般/差美容率2.9%(n=7)。
- 多数患者无急性毒性:55%皮炎0级,57%乏力0级,97%瘙痒0级。
临床怎么用
- 在严格轮廓勾画、剂量学及规划指南下,可考虑将每日两次或隔日EB-APBI用于合适选择的患者。
- 采用多野三维适形、俯卧位技术有助于降低急毒性并改善美容效果。
- 关注患侧乳腺V100等剂量体积参数,可能有助于减少一般/差美容发生率。
局限性
- 回顾性设计,中位随访仅19个月,需更长随访确认美容效果稳定性。
- 单中心经验,样本量245例,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Two randomized controlled trials of external beam accelerated partial breast irradiation (EB-APBI) using 38.5 Gy/10 fractions twice daily demonstrated excellent cancer control outcomes in appropriately selected patients, but with conflicting results regarding cosmesis. A recent randomized controlled trial reported high rates of acceptable cosmesis using 30 Gy/5 fractions every other day, calling into question the most appropriate schedule for EB-APBI. Our accelerated partial breast irradiation approach uses strict contouring, dosimetric, and planning guidelines. We report our experience with twice-daily and every-other-day EB-APBI, hypothesizing that our treatment planning approach would result in acceptable acute toxicity and cosmesis. METHODS AND MATERIALS: We identified patients who received EB-APBI from April 2017 to December 2021. Clinical, pathologic, acute toxicity, cosmesis, and dosimetric data for the lumpectomy gross tumor volume, clinical target volume, and planning target volume were collected. Cosmesis was physician-reported using the 4-point Radiation Therapy Oncology Group (RTOG) global cosmetic score: excellent, good, fair (F), and poor (P). We report descriptive statistics to summarize our results. RESULTS: A total of 245 patients were included with a median follow-up of 19 months (IQR, 9-30 months); the median age was 66 years (IQR, 59-71 years), 82% had invasive breast cancer, 100% had invasive tumors that were hormone-receptor positive/human epidermal growth factor receptor 2 negative, and 96% had nodal surgery for invasive disease. Fractionation was twice daily in 55% of patients, and every other day in 45%. Three-dimensional conformal radiation was used in 88%, with a median of 6 fields, and 96% were treated prone. Most patients had no acute toxicity (55% grade 0 dermatitis; 57% grade 0 fatigue; 97% grade 0 pruritis). The rate of excellent/good cosmesis was 97.1% (n = 238), and F/P was 2.9% (n = 7). The ipsilateral breast V100 was marginally associated with increased odds of F/P cosmesis (odds ratio, 1.18; 95% CI, 0.99-1.42; P = .07). CONCLUSIONS: With multiple-field 3-dimensional conformal radiation in the prone position, EB-APBI can be delivered with extremely low toxicity and great cosmetic results with twice-daily or every-other-day fractionation. Given the low rate of F/P cosmesis, longer follow-up is needed to confirm the stability of these results and to help identify optimal planning dose-volume parameters to help minimize the rate of F/P cosmesis.
引用
- Bazan JG, Jhawar SR, Beyer S, et al. Favorable Rates of Excellent or Good Cosmetic Outcomes in Patients Treated With Carefully Planned Accelerated Partial Breast Irradiation Delivered Twice Daily or Once Every Other Day. Pract Radiat Oncol. 2025. PMID: 40318754. doi:10.1016/j.prro.2025.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。